Today Stories

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are excited to announce a major distribution agreement. This partnership will bring GTG's innovative Multi-Risk Test to a broader audience in the online pharmacy channel across North America, empowering individuals to take control of their health. Stayhealthy is at the forefront of integrating technology with health solutions. The company's mission is to empower, inspire, and give hope to individuals, families, and communities through enhanced technology and a global wellness network. Their FDA-cleared technologies ha…

AstraZeneca today announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabili…

Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of OmniSeq® INSIGHT circulating tumor DNA BURLINGTON, N.C., June 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced new strategic service offerings within its precision oncology portfolio. The enhancements strengthen Labcorp's leadership as a premier, single-source partner for biopharmaceutical companies in advancing cancer research and patient care both in the United States and globally. "Labcorp's portfolio expansion enhances our integrated service offerings a…

Collaboration leverages synergies of QIAGEN’s OmicSoft omics data through Evotec’s analysis platform PanHunter Customers accelerate target discovery decisions with high-quality multi-omic evidence, and expanded analysis capabilities Hamburg, Germany, and Venlo, the Netherlands, 03 June 2024:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to leverage QIAGEN’s OmicSoft Land Databases through Evotec’s PanOmics data access and analysis platform PanHunter. Combining comprehensive data sets with advanced analytics capabilities will enable enhanced multi-omics data insights, better disease understanding and more precise therapeutic interventions. Omics data offers exten…

In the MCL cohort of TRANSCEND NHL 001, Breyanzi delivered responses in 85.3% of patients with a one-time infusion while demonstrating a consistent safety profile across clinical trials Breyanzi is the only CAR T cell therapy approved by the FDA for four distinct subtypes of non-Hodgkin lymphoma, bringing this personalized therapy to the broadest array of patients with B-cell malignancies PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of s…

Partnership will expand Evotec’s molecular patient database in the area of metabolic diseases and in particular obesity Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics Lille University Hospital will provide human biological samples and associated clinical data from its ABOS Biobank and will collect specific human biosamples for the collaboration All parties will jointly identify and validate novel key mechanisms of obesity & other metabolic diseases based on human data sets Hamburg, Germany, 30 May 2024:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company entered a partnership with Inserm, the French National Ins…

The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia. HEIDELBERG, Germany, May 28, 2024 – German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders. The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies. This research project was launched in 2020 at the BioMed X Institute in Heidelberg and led by Dr. Ebru Ercan Herbst, now a professor at Reutlingen University, Germany. Her team has created both in vivo and in vitro platfo…

DUBLIN, May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States. This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live. Life Science Cares is a collective effort to activate the financial and human capital of the life sciences industry across several regions in the U.S. – and partner with nonprofits – to disrupt the cycle of poverty and inequality in those communities. With hubs around Jazz's U.S. offices in Palo Alto, Philadelphia and San Diego, Life Science Cares will help enable Jazz's goals to harness the passion of its employees to make a meaningful difference in their communities…

Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced a major expansion of their partnership. Two new projects to develop first-in-class treatments will be added to the ongoing anti-SIRPα immuno-oncology programs. The first involves broadening the therapeutic evaluation of an already partnered asset to reach more patients and the other a new asset acquisition: Reflecting an amendment of the existing collaboration and license agreement for the anti-SIRPα immuno-oncology compounds BI 765063 and BI 770371, which are being investigated in Phase I clinical studies in advanced solid tumors, development will now also be pursued in cardiovascular-renal-metabolic (CRM) diseases. A new preclinical program will…

Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries. Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues on its path to becoming the first biopharma company powered by AI at scale. Paul Hudson CEO, Sanofi“This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substan…

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. Manufacturing of ADCs is a multi-step process that comprises antibody production, synthesis of chemotherapy drug and linker, conjugat…

A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis. RIDGEFIELD, CT, May 16, 2024 – XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim camp in Ridgefield, Connecticut. This research team’s main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently. The new research team is led by Dr. Lo…

DEERFIELD, Ill. - 2024-05-15 Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive. The Vantive mission, Extending Lives, Expanding Possibilities, will guide and inspire the proposed company, which will focus on vital organ therapies for acute and chronic kidney diseases and beyond. This larger purpose will drive Vantive employees to passionately develop solutions that meet the very human and often very individual needs of clinicians and patients, always striving to shape a better healthcare experience.   The Vantive logo includes a "V" motif divided into three parts to represent the innovative therapies, digital solutions, and advanced services the company delivers.…

More than half of all U.S. cervical cancer patients are underscreened1, which makes reducing barriers to sample collection and increasing access to screenings crucial to ultimately helping eliminate this deadly disease. Each year in the U.S., more than 13,000 patients are diagnosed with cervical cancer and approximately 4,000 die from this preventable disease, caused by HPV infection.1 Roche’s human papillomavirus (HPV) self-collection solution will improve access to testing by providing women the option to privately collect their own sample. Basel, 15 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the FDA approval of its human papillomavirus (HPV) self-collection solution, one of the first available in the United States. Screening for HPV can help identify women who are a…

-   Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHICAGO, Ill. and NEW YORK, May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel neuroplastogens. Classic psychedelic compounds provide novel mechanisms to address mental health disorders, and some have shown promising clinical efficacy where other treatments have been ineffective. However, these first-generation comp…

The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics. This approach could potentially be adapted for diagnosis of other neurological conditions. WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially est…

Axmed’s B2B marketplace aggregates demand for critical medicines in underserved regions to improve the availability, affordability, and distribution of life-saving medicine while extending manufacturer footprints in new markets.   Basel, Switzerland – May 8, 2024: For too long, low- and middle-income countries (LMICs) have borne the brunt of global health disparities—accounting for over 80% of the world's population and more than 90% of its disease burden—yet representing a mere 6% of global pharmaceutical revenue. Equitable access to high quality affordable medicines remains a daunting task, and addressing this challenge has never been more critical. Axmed, an innovative two-sided B2B marketplace platform, is taking a bold and meaningful step forward in addressing this disparity with the…

7 May 2024 UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology firm based at Alderley Park – has been awarded the King’s Award for Enterprise after achieving a triple-figure revenue growth following rapid expansion in international markets. Gentronix recorded total growth of 239% in overseas earnings over the past three years, with the percentage of total sales exported rising from 71% to 81% over the same period, driving revenue to in excess of £10m per annum. The US has been a particularly strong area of growth and this market now makes up almost half of the firm’s international business, with demand continuing to increase across North America. As a result of the business’s success and enhanced overseas trading, Gentronix has received a prestigious K…

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1  DMI is a common, irreversible complication of diabetic retinopathy (DR) that may lead to blindness.1,2,3,4­ It can develop when the light sensitive tissues of the central retina do not receive adequate blood supply over a longer time. There are currently no approved treatments for DMI.  The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasi…

Noninvasive urine-based biomarker testing can support routine testing for graft dysfunction WEST HILLS, Calif.--(BUSINESS WIRE)-- For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of rejection, both of which may carry complications. Now, a simple, urine-based assay that detects the CXCL10 chemokine may make care more convenient and less invasive for the nearly 250,000 Americans living with a kidney transplant. Thermo Fisher Scientific One Lambda Laboratories, a CLIA facility in Fishers, Ind., has introduced a new CXCL10 testing service, which allows for non-invasive urine sample collection and testing, with results available in as little as 24 hours, providing valuable information faster th…